Researchers detail the use of a drug that may help block the way glioblastoma brain cancer cells respond to fluid flow. The finding could lead to stopping glioblastoma from spreading.
A new study reports a genetically modified poliovirus therapy has been shown to improve long term survival rates in recurrent glioblastoma brain cancer patients. Researchers say the therapy had a three year survival rate for 21 percent of participants in a phase 1 clinical trial, compared to just 4% of patients who received more standard treatments.
Researchers at MIT have developed a new drug delivering nanoparticle that is able to cross the blood-brain barrier. The nanoparticles carry two different drugs that can help shrink tumors and prevent them from growing back.
Researchers use gene editing to generate aggressive glioblastoma multiforme brain tumors in the lab. The model, researchers say, could be used to track the progression of tumors and develop personalized therapies for patients.
Researchers report the addition of an FDA approved chemotherapy drug called hydroxyyurea to temozolomide helps to increase survival rates in animal models of glioblastoma.
A new drug has been cleared for human trials in patients with anaplastic astrocytoma and glioblastoma brain cancers. The drug, PAC-1, is reported to spur cancer cells to self destruct and has proven to be effective in animal models of brain cancers.
Arsenic trioxide, a treatment used for acute promyelocytic leukemia, may help extend lifespan in patients with glioblastoma brain cancer, a new study reports.
Researchers have identified a biomarker that can help predict a patient's prognosis and response to therapies for glioblastoma brain cancer subtypes.